Javascript must be enabled to continue!
Research on animal models of chronic dacryocystitis in dogs
View through CrossRef
Abstract
Objective
To explore an ideal animal model of chronic dacryocystitis.
Methods
(1) The anatomical structure of the lacrimal drainage system in dogs was observed; (2) The canine lacrimal drainage system was obstructed by cauterization of the nasolacrimal duct; (3) A canine model of dacryocystitis was established by combining nasolacrimal duct cauterization with inoculation of Staphylococcus aureus.
Results
Compared with inoculation of Staphylococcus aureus one week after nasolacrimal duct cauterization, the combined method of nasolacrimal duct cauterization and immediate inoculation of Staphylococcus aureus induced clinical manifestations of dacryocystitis more rapidly in dogs. The modeling success rate was 83.3%.
Conclusion
Our experimental data demonstrate that the anatomical structure of the canine lacrimal duct is similar to that of humans, providing a solid anatomical foundation for modeling chronic dacryocystitis. The method of nasolacrimal duct cauterization combined with Staphylococcus aureus injection can rapidly and effectively induce canine dacryocystitis manifestations while being simple and feasible to perform. Therefore, dogs can be considered as a suitable animal model for further research on chronic dacryocystitis. This model reliably reproduces key pathological features—including chronic inflammation, ductal obstruction, and bacterial persistence—enabling mechanistic studies and therapeutic evaluation. Its reproducibility and clinical relevance support translational applications in developing novel interventions for human chronic dacryocystitis. If a more persistent chronic inflammatory model is to be constructed, further optimization of surgical parameters and inoculation protocols will still be required.
Springer Science and Business Media LLC
Title: Research on animal models of chronic dacryocystitis in dogs
Description:
Abstract
Objective
To explore an ideal animal model of chronic dacryocystitis.
Methods
(1) The anatomical structure of the lacrimal drainage system in dogs was observed; (2) The canine lacrimal drainage system was obstructed by cauterization of the nasolacrimal duct; (3) A canine model of dacryocystitis was established by combining nasolacrimal duct cauterization with inoculation of Staphylococcus aureus.
Results
Compared with inoculation of Staphylococcus aureus one week after nasolacrimal duct cauterization, the combined method of nasolacrimal duct cauterization and immediate inoculation of Staphylococcus aureus induced clinical manifestations of dacryocystitis more rapidly in dogs.
The modeling success rate was 83.
3%.
Conclusion
Our experimental data demonstrate that the anatomical structure of the canine lacrimal duct is similar to that of humans, providing a solid anatomical foundation for modeling chronic dacryocystitis.
The method of nasolacrimal duct cauterization combined with Staphylococcus aureus injection can rapidly and effectively induce canine dacryocystitis manifestations while being simple and feasible to perform.
Therefore, dogs can be considered as a suitable animal model for further research on chronic dacryocystitis.
This model reliably reproduces key pathological features—including chronic inflammation, ductal obstruction, and bacterial persistence—enabling mechanistic studies and therapeutic evaluation.
Its reproducibility and clinical relevance support translational applications in developing novel interventions for human chronic dacryocystitis.
If a more persistent chronic inflammatory model is to be constructed, further optimization of surgical parameters and inoculation protocols will still be required.
Related Results
The microbiologic spectrum of dacryocystitis
The microbiologic spectrum of dacryocystitis
Abstract
Background
To investigate the microbiologic spectrum of dacryocystitis in adult and pediatric groups, specifically the microbiologic differences between chronic d...
The microbiologic spectrum of dacryocystitis
The microbiologic spectrum of dacryocystitis
Abstract
Background: To investigate the microbiologic spectrum of dacryocystitis in adult and pediatric groups, specifically the microbiologic differences between chronic d...
The microbiologic spectrum of dacryocystitis
The microbiologic spectrum of dacryocystitis
Abstract
Background: To investigate the microbiologic spectrum of dacryocystitis in adult and pediatric groups, specifically the microbiologic differences between chronic d...
The microbiologic spectrum of dacryocystitis
The microbiologic spectrum of dacryocystitis
Abstract
Background: To investigate the microbiologic spectrum of dacryocystitis in adult and pediatric groups, specifically the microbiologic differences between chronic d...
MICROBIOLOGICALAND CLINICAL SPECTRUM IN CHRONIC DACRYOCYSTITIS
MICROBIOLOGICALAND CLINICAL SPECTRUM IN CHRONIC DACRYOCYSTITIS
Background: Dacryocystitis is the inammation of the lacrimal sac which is usually because of nasolacrimal duct obstruction. It is a major cause of ocular morbidity especially in f...
Electric Animal An Interview with Akira Mizuta Lippit & (untitled photographs)
Electric Animal An Interview with Akira Mizuta Lippit & (untitled photographs)
Dr. Akira Mizuta Lippit, author of Electric Animal: Toward a Rhetoric of Wildlife, explores, in the context of the development of cinema, how the concept of “the animal” has become...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...

